TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02726646

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Mechanical debridement
Description: Mechanical debridement (full mouth) of 45 minutes associated with the application of 1 mg of microspheres placebo in selected periodontal pockets.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical debridement
Description: Mechanical debridement (full mouth) of 45 minutes associated with the application of 1 mg of microspheres placebo in selected periodontal pockets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The application of 1 mg of microspheres placebo
Study: NCT03954756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib and PD1
Description: 1. Apatinib starting dose of 500mg, qd, oral, taken half an hour after a meal~2. PD-1 was administered 200mg (3mg/kg for underweight patients) iv every 2 weeks.
Study: NCT00750204

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APRV
Description: APRV Protocol~* Set fraction of inspired oxygen (FiO2) at 0.1 higher than the setting on conventional MV currently used~* Tlow = 1.0 second (this setting shall remain unchanged throughout the trial).~* Respiratory rate (RR) to equal 60-65% of RR on conventional MV.~* P high = the inspiratory plateau pressure. Maximum P high = 30 cm H20.~* Plow = 5 cm water (H2O). Adjust Plow to achieve pressure release volumes 5.5-6.5 ml/kg of percent body weight (PBW).~* If release volumes on APRV are greater than desired, increase Plow by 2-4 cm H2O increments to a maximum of Plow = 12 cm H2O. If release volumes are larger than desired despite raising Plow to 12 cm H20, decrease P high in increments of 2-4 cm H20 to achieve desired release volumes (minimum P high = 12 cm H20). If release volumes on APRV still remain larger than desired,the participant will be excluded from the study and placed on conventional MV.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional MV
Description: Low tidal-volume mechanical ventilation
Study: NCT02519192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V.A.C.Ulta™ Negative Pressure Wound Therapy System
Description: VAC Arm will consist of a group of patients assigned to VAC negative pressure therapy with regular sponge irrigation with normal saline (the V.A.C.Ulta™ Negative Pressure Wound Therapy System) .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vac sponge irrigations
Description: VAC Arm will consist of a group of patients assigned to VAC negative pressure therapy with regular sponge irrigation with normal saline (the V.A.C.Ulta™ Negative Pressure Wound Therapy System) .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ostomy bag
Description: Non Vac Arm will receive ostomy bag applications.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: wet to dry dressings
Description: Non Vac arm will receive wet to dry dressing changes.
Study: NCT04672928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 80mg/m\^2,iv,Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI318
Description: 300mg,iv,Q4W
Study: NCT00647790

Intervention type: PROCEDURE
Intervention: PET scan with injection of 5-8 mCi of 18FES
Description: Following injection of the tracer 18FES, dynamic images will be obtained for 30 minutes over the chest area to include cardiac region and breasts. Following the first dynamic imaging for 30 minutes, whole body images (base of skull to pelvis) will be obtained at 5 minute/bed position. An additional, longer scan after 60 minutes will be obtained for the chest (1-2-FOV for 15 minutes each). Total time from injection to completion of imaging will be about 90 minutes.
Study: NCT03590379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5993 DPI
Description: BDP/FF/GB DPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF5993 pMDI
Description: BDP/FF/GB pMDI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 1535 pMDI
Description: BDP/FF pMDI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo DPI
Description: CHF 5993 DPI matched placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo DPI
Description: CHF 5993 DPI matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pMDI
Description: CHF 5993 pMDI matched Placebo (direct blinding of active CHF 5993 and CHF 1535 pMDIs)
Study: NCT00378196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.3 mg/0.05 ml dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.5 mg/0.05 ml dose
Study: NCT00924456

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation program
Description: a natural effortless mental technique

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Transcendental Meditation program
Description: a natural effortless mental technique
Study: NCT01554384

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF assay
Description: Automated nucleic-acid amplification test (fully integrated) test for TB

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Smear microscopy
Description: Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading
Study: NCT02625259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-117
Description: TAK-117 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-117
Description: TAK-117 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-117
Description: TAK-117 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-117
Description: TAK-117 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-117
Description: TAK-117 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-117
Description: TAK-117 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-117
Description: TAK-117 tablets
Study: NCT01075945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin- piperaquine
Description: three tablets per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemether- lumefantrine
Description: twenty tablet in eight doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artemether- lumefantrine
Description: twenty tablet in eight doses
Study: NCT01905657

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: IV infusion
Study: NCT02955485

Intervention type: OTHER
Intervention: Patients do not undergo any type of interventions, but standard care if offered and accepted.

Intervention type: OTHER
Intervention: Patients do not undergo any type of interventions, but standard care if offered and accepted.
Study: NCT01010516

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High-dose rosuvastatin
Description: 40 of rosuvastatin daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin plus fenofibrate
Description: Existing statin plus micronised fenofibrate 200 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin plus niacin ER/laropiprant
Description: Existing statin plus extended-release niacin/laropiprant (1 g/day for the first month which will be uptitrated to 2 g/day for the next months)
Study: NCT01737151

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: stereotactic body radiation therapy
Description: Undergo SBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: four fraction split-course SBRT
Description: four fraction split-course SBRT
Study: NCT01409655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive-behavioral therapy
Description: . Reinforcement for medication-taking will be wired to debit cards that patients will be given to receive the payments. This contingent reinforcement of medication-taking will be coupled with twelve sessions of cognitive-behavioral therapy (CBT) conducted by phone, also assisted by the website which will generate CBT-related text messages, reminders and scheduling information from a menu of choices negotiated by the patient and therapist.
Study: NCT02538250

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutricomp Drink Plus
Description: Oral nutritional supplementation
Study: NCT01896440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: There will be two doses investigated in each arm - standard dose (0.15 mg/kg) and high dose (0.3 mg/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: There will be two doses investigated in each arm - standard dose (0.15 mg/kg) and high dose (0.3 mg/kg)
Study: NCT03915496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842 200 mg
Description: PF-04965842 200 mg administered as two tablets to be taken orally once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842 100 mg
Description: PF-04965842 100 mg administered as two tablets to be taken orally once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as two tablets to be taken orally once daily for 12 weeks
Study: NCT00664391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactic acid (Dermacid)
Description: Liquid soup to be applied in the external genital area, in small quantity, with abundantly rinse after use, during 21 days
Study: NCT02303301

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Cultures from the oropharynx

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cultures from the oropharynx
Study: NCT03755492

Intervention type: OTHER
Intervention: Absorbent pad for urinary incontinence
Description: 6 month supply provided to patients as needed for urinary incontinence after radical prostatectomy
Study: NCT01058109

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: calcium-rich diet
Description: dietary calcium intake of 1500 mg/d

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calcium rich diet
Description: dietary intake of 1500 mg/d from food
Study: NCT03619486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low energy shock wave
Description: Probe be transcutaneous applied to the suprapubic bladder region with 2000 shocks, frequency of 3 pulses per second and maximum total energy flow density 0.25 millijoule/mm2 once a week for 4 weeks

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Probe be transcutaneous applied to the suprapubic bladder region with 2000 shocks, frequency of 3 pulses per second but no energy once a week for 4 weeks
Study: NCT02513290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Study: NCT02534558

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: miR 29a
Description: Effects of IL-1β, miR-29a precursor or antisense oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: miR 29a
Description: Effects of IL-1β, miR-29a precursor or antisense oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
Study: NCT00169234

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV7, Prevnar®
Description: Randomized to receive 0.1mL, 0.5mL, 1.0mL or 2.0mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV7, Prevnar®
Description: Randomized to receive 0.1mL, 0.5mL, 1.0mL or 2.0mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV7, Prevnar®
Description: Randomized to receive 0.1mL, 0.5mL, 1.0mL or 2.0mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV7, Prevnar®
Description: Randomized to receive 0.1mL, 0.5mL, 1.0mL or 2.0mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax 23
Description: Randomized to receive 0.5mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax 23
Description: Randomized to receive 0.5mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax 23
Description: Randomized to receive 0.5mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax 23
Description: Randomized to receive 0.5mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax 23
Description: Randomized to receive 0.5mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.
Study: NCT01986309

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Bolus 1.5 mg/kg over 5 minutes, then an infusion of 2 mg/kg/h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Sodium Chloride 0.9% infusion
Study: NCT01164696

Intervention type: DRUG
Intervention: [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)
Description: Zevalin was administered according to the directives in the approved package leaflet.
Study: NCT06608953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation
Description: A device applying external pneumatic cuff pressure to the lower limbs, thighs, and buttock sequentially in the diastolic phase synchronouslty with electrocardiography to assist the cardiac function via diastolic augmentation mechanism.
Study: NCT04193085

Intervention type: OTHER
Intervention: Observational
Description: Observational

Intervention type: OTHER
Intervention: Observational
Description: Observational

Intervention type: OTHER
Intervention: Observational
Description: Observational
Study: NCT03532854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan P.O

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan P.O

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan P.O

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan P.O

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan P.O

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan P.O

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Rosuvastatin
Description: Ezetimibe/Rosuvastatin P.O

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Rosuvastatin
Description: Ezetimibe/Rosuvastatin P.O

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Rosuvastatin
Description: Ezetimibe/Rosuvastatin P.O

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Rosuvastatin
Description: Ezetimibe/Rosuvastatin P.O

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Rosuvastatin
Description: Ezetimibe/Rosuvastatin P.O

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Rosuvastatin
Description: Ezetimibe/Rosuvastatin P.O
Study: NCT03305549

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative dialysis strategy
Description: Participants will receive RRT only when meeting 1 of the following indications (patterned after the AKIKI trial's delayed RRT initiation arm):~* Blood urea nitrogen \>112 mg/dL (40 mmol/L)~* Serum potassium concentration \>6 mmol/L~* Serum potassium concentration \>5.5 mmol/L despite medical treatment (e.g., bicarbonate, glucose-insulin infusion, albuterol, diuretics, sodium polystyrene sulfonate)~* Arterial blood gas pH \<7.15 in a context of pure metabolic acidosis (PaCO2 \<35 mmHg) or in a context of mixed acidosis with PaCO2 50 mmHg despite medical treatment to reverse respiratory acidosis (e.g., naloxone), or in the absence of an available arterial blood gas, serum bicarbonate \<12 mmol/L~* Acute pulmonary edema due to fluid overload, responsible for hypoxemia requiring oxygen flow rate \>5 L/min to maintain SpO2 \>95% or requiring FiO2 \>50% in patients already on invasive or non-invasive mechanical ventilation and despite diuretic therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TIW dialysis strategy
Description: Thrice-weekly acute intermittent hemodialysis schedule.
Study: NCT04741958

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Peripheral Thoracic Tumors
Description: Transthoracic ultrasonography: Transthoracic US was done using machine Hitachi 5500 in the Diagnostic Ultrasound Unit - Chest Department- Kasr El-Aini Hospital.on 60 patients that had radiographic evidence of thoracic mass suspected of malignancy
Study: NCT04348149

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lindera obtusiloba extract
Description: One package of dietary supplement contains one gram of 70% ethanol extracted powder of Lindera obtusiloba and one gram of glucose powder. Participants intake one package per day for 8 weeks.
Study: NCT00561002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2007-2008 Influenza Virus Vaccine
Description: 0.25 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2007-2008 Influenza Virus Vaccine
Description: 0.25 mL, Intramuscular
Study: NCT01809145

Intervention type: OTHER
Group type: OTHER
Intervention: MELISA test
Description: MELISA test for hypersensitivity to metals in sarcoidosis
Study: NCT01817699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Hb target
Description: 25 to 250 μg of methoxy polyethylene glycol epoetin beta (Mircera®, Chugai pharmaceutical Co. Ltd.) will be administered subcutaneously at 2- to 6-week interval.~Dose and interval will be adjusted according to hemoglobin level and its target.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Hb target
Description: 25 to 250 μg of methoxy polyethylene glycol epoetin beta (Mircera®, Chugai pharmaceutical Co. Ltd.) will be administered subcutaneously at 2- to 6-week interval.~Dose and interval will be adjusted according to hemoglobin level and its target.
Study: NCT01798004

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous peripheral blood stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study: NCT01817699

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: 1,000 IU (1 tablet)/day, orally. Tablets are repacked into blister package.
Study: NCT01798004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT
Study: NCT01817699

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: 1,000 IU (1 tablet)/day, orally. Tablets are repacked into blister package.
Study: NCT01713283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT03262350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: The yoga classes will be adapted to all levels of experience, mobility, and body size. Specific breathing techniques and body positive language will be incorporated into a body-positive yoga training done by Ms. Lisa Diers, RDN, E-RYT, YACEP. Less focus will be placed on precision of the poses, instead focus will be on body feelings, except where physically dangerous. Thus, the overall focus will be on listening to one's own body. List of messages will be carefully designed to be related to eating and weight, but to not be directly discussed. Ms. Diers will travel to Delaware to lead the intervention training for yoga instructors prior to the study taking place.
Study: NCT02626234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Study: NCT02690428

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immunostimulating Interstitial Laser Thermotherapy
Description: Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
Study: NCT03993990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: individual empowerment-based intervention
Description: Participants will receive an empowerment-based intervention individually, based on five steps (i. e. problem identification, meaning and perception clarification, intervention planning, intervention delivery, and evaluation). After the principal investigator delivers a pre-discharge assessment (i. e. the self-care behavior and self-efficacy of diabetes and diabetic foot ulcer, risk factors of foot ulcer, family support, and threat belief of participant), the plan of behavioral modification will be determined by the principal investigator and participants. The subsequent follow-up and intensifying interventions will be delivered at the following time points: three days after discharge, every weeks for one month, every two weeks for subsequent two months, and then every three months for three times.